These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36965744)

  • 1. Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression.
    Kawarasaki S; Sawazaki H; Iijima H; Takahashi H; Nomura W; Inoue K; Kawada T; Goto T
    Eur J Pharmacol; 2023 May; 947():175682. PubMed ID: 36965744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.
    Fukuda-Tsuru S; Kakimoto T; Utsumi H; Kiuchi S; Ishii S
    Eur J Pharmacol; 2014 Jan; 723():207-15. PubMed ID: 24309217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
    Kadowaki T; Inagaki N; Watada H; Sasaki K; Mori-Anai K; Iwasaki T; Teranishi T
    Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Gouda M; Iijima H; Watanabe Y
    Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study.
    Son C; Makino H; Kasahara M; Tanaka T; Nishimura K; Taneda S; Nishimura T; Kasama S; Ogawa Y; Miyamoto Y; Hosoda K
    Diabetes Res Clin Pract; 2021 Oct; 180():109037. PubMed ID: 34481910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
    Fushimi Y; Obata A; Sanada J; Iwamoto Y; Mashiko A; Horiya M; Mizoguchi-Tomita A; Nishioka M; Kan Y; Kinoshita T; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Res; 2020; 2020():4861681. PubMed ID: 32337293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro.
    Wei D; Liao L; Wang H; Zhang W; Wang T; Xu Z
    Life Sci; 2020 Apr; 247():117414. PubMed ID: 32035928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
    Cho KY; Nomoto H; Nakamura A; Kawata S; Sugawara H; Takeuchi J; Nagai S; Tsuchida K; Omori K; Yokoyama H; Manda N; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    Diabetes Obes Metab; 2020 Mar; 22(3):458-462. PubMed ID: 31486230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Iijima H; Watanabe Y; Gouda M
    Diabetes Obes Metab; 2017 Jun; 19(6):874-882. PubMed ID: 28177187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
    Ceriello A; De Nigris V; Iijima H; Matsui T; Gouda M
    Drugs; 2019 May; 79(7):733-750. PubMed ID: 30982160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
    Okahata S; Sakamoto K; Mitsumatsu T; Kondo Y; Tanaka S; Shiba T
    Diabetes Obes Metab; 2019 Feb; 21(2):388-392. PubMed ID: 30146790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment of dipeptidyl peptidase-4 inhibitor and exercise training improves lipid profile in KK/Ta mice.
    Tanimura Y; Aoi W; Mizushima K; Higashimura Y; Naito Y
    Exp Physiol; 2019 Jul; 104(7):1051-1060. PubMed ID: 31020720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
    Cho KY; Nomoto H; Nakamura A; Kawata S; Sugawara H; Takeuchi J; Nagai S; Omori K; Tsuchida K; Miya A; Shigesawa I; Tsuchida K; Yanagiya S; Kameda H; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Nishimoto N; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Aug; 12(8):1417-1424. PubMed ID: 33421309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
    Miya A; Nakamura A; Cho KY; Kawata S; Nomoto H; Nagai S; Sugawara H; Taneda S; Tsuchida K; Omori K; Yokoyama H; Takeuchi J; Aoki S; Kurihara Y; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Aug; 12(8):1395-1399. PubMed ID: 33325645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy.
    Xu Z; Hu W; Wang B; Xu T; Wang J; Wei D
    Yonsei Med J; 2022 Jul; 63(7):619-631. PubMed ID: 35748073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice.
    Naznin F; Sakoda H; Okada T; Tsubouchi H; Waise TM; Arakawa K; Nakazato M
    Eur J Pharmacol; 2017 Jan; 794():37-44. PubMed ID: 27876617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.